Top Ranked Momentum Stocks to Buy for March 21st

Zacks Equity Research - finance.yahoo.com Posted 5 years ago
image

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, March 21st:

Bio-Rad Laboratories, Inc. (BIO): This manufacturer of products and solutions for life science research has a Zacks Rank #1 (Strong Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 5.6% over the last 60 days.

Bio-Rad Laboratories, Inc. Price and Consensus

View photos
Bio-Rad Laboratories, Inc. Price and Consensus
More

Bio-Rad Laboratories, Inc. price-consensus-chart | Bio-Rad Laboratories, Inc. Quote

Bio-Rad Laboratories’ shares gained 13.3% over the last one month against the S&P 500’s rise of 1.8%. The company possesses a Momentum Score of B.

Bio-Rad Laboratories, Inc. Price

View photos
Bio-Rad Laboratories, Inc. Price
More

Bio-Rad Laboratories, Inc. price | Bio-Rad Laboratories, Inc. Quote

DENTSPLY SIRONA Inc. (XRAY): This dental and oral health products manufacturer has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 5.5% over the last 60 days.

DENTSPLY SIRONA Inc. Price and Consensus

View photos
DENTSPLY SIRONA Inc. Price and Consensus
More

DENTSPLY SIRONA Inc. price-consensus-chart | DENTSPLY SIRONA Inc. Quote

DENTSPLY SIRONA’s shares gained 17.4% over the last one month. The company possesses a Momentum Score of A.

DENTSPLY SIRONA Inc. Price

View photos
DENTSPLY SIRONA Inc. Price
More

DENTSPLY SIRONA Inc. price | DENTSPLY SIRONA Inc. Quote

Lantheus Holdings, Inc. (LNTH): This diagnostic medical imaging agents and products manufacturer has a Zacks Rank #2 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 17.2% over the last 60 days.

Lantheus Holdings, Inc. Price and Consensus

View photos
Lantheus Holdings, Inc. Price and Consensus
More

Lantheus Holdings, Inc. price-consensus-chart | Lantheus Holdings, Inc. Quote

Lantheus’ shares gained 16.4% over the last one month. The company possesses a Momentum Score of A.

Lantheus Holdings, Inc. Price

View photos
Lantheus Holdings, Inc. Price
More

Lantheus Holdings, Inc. price | Lantheus Holdings, Inc. Quote

Masimo Corporation (MASI): This medical technology company has a Zacks Rank #2 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 1.3% over the last 60 days.

Masimo Corporation Price and Consensus

View photos
Masimo Corporation Price and Consensus
More

Masimo Corporation price-consensus-chart | Masimo Corporation Quote

Masimo’s shares gained 3.7% over the last one month. The company possesses a Momentum Score of A.

Masimo Corporation Price

View photos
Masimo Corporation Price
More
Story continues

Masimo Corporation price | Masimo Corporation Quote

See the full list of top ranked stocks here.

Learn more about the Momentum score and how it is calculated here.

Zacks' Top 10 Stocks for 2019

In addition to the stocks discussed above, wouldn't you like to know about our 10 finest buy-and-holds for the year?

From more than 4,000 companies covered by the Zacks Rank, these 10 were picked by a process that consistently beats the market. Even during 2018 while the market dropped -5.2%, our Top 10s were up well into double-digits. And during bullish 2012 – 2017, they soared far above the market's +126.3%, reaching +181.9%.

This year, the portfolio features a player that thrives on volatility, an AI comer, and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs.

See Stocks Today >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
DENTSPLY SIRONA Inc. (XRAY) : Free Stock Analysis Report
 
Masimo Corporation (MASI) : Free Stock Analysis Report
 
Lantheus Holdings, Inc. (LNTH) : Free Stock Analysis Report
 
Bio-Rad Laboratories, Inc. (BIO) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research